Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG

  1. March 18, 2024

    2nd Circ. Rejects 'New Standard' Of Patent Monopolies

    A Second Circuit panel on Monday revived antitrust allegations accusing Novartis of concealing the true history of an eye syringe treatment's development from the U.S. Patent and Trademark Office to edge Regeneron out of the market, faulting a district court for holding that antitrust markets can't be "coextensive" with the patent.

  2. October 05, 2023

    IP Forecast: Novartis To Fight Antitrust Row Over Drug Patent

    Novartis is set to oppose an appeal at the Second Circuit from a rival seeking to restore an antitrust suit accusing it of hiding things from the patent office to illegally corner the market for an eye syringe treatment. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.